The Latest Guidance on IBS-C Pharmacological Management: The Lead Author’s Perspective
Lin Chang, MD, AGAF spoke with Physician’s Weekly about the guideline and the overall topic of pharmacological management of IBS-C.
Lin Chang, MD, AGAF spoke with Physician’s Weekly about the guideline and the overall topic of pharmacological management of IBS-C.
An innovative, curated ebook featuring insightful IBS-C findings and input from key opinion leaders in the field of gastroenterology.
Physician’s Weekly recently spoke with Linda Girgis, MD, FAAFP, about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, lead author of the phase 3 T3MPO-2 study—which assessed the efficacy of the NHE3 inhibitor tenapanor in treating patients with irritable bowel syndrome with constipation (IBS-C)—about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Physician’s Weekly recently spoke with Lin Chang, MD, AGAF, lead author of the 2022 AGA Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation (IBS-C).
Physician’s Weekly recently spoke with Brooks Cash, MD about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Physician’s Weekly recently spoke with Satish SC Rao, MD, PhD, FRCP, FACG, AGAF about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, the lead...
Physician’s Weekly recently spoke with Brian E. Lacy, MD, PhD, a board-certified...
PW QUIZ
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.